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Objectives: To analyse the association between adherence to anti-diabetic therapy (diet, physical activity and medications) and 
perinatal outcomes.
Methods: A cohort design was used. Participants were 157 pregnant women with diabetes, and the setting was Mbuya Nehanda 
and Chitungwiza Maternity Hospitals, Harare, Zimbabwe.
Results: Main outcome measures were maternal and perinatal outcomes. Mean adherence to anti-diabetic therapy was 66.7%. 
Perinatal outcomes observed were hypertensive disorders (34.5%), Caesarean delivery (45.9%), maternal diabetic ketoacidosis 
(5.1%), maternal hypoglycaemia (15.9%), and candidiasis (19.7%). Neonatal outcomes were perinatal mortality (15.9%), low 
Apgar score at 1 minute (26.8%), low Apgar score at 5 minutes (24.8%), macrosomia (33.8%), neonatal hypoglycaemia (15.3%), 
and neonatal hyperbilirubinemia (7.6%). There were significant associations between adherence and Caesarean delivery (RR 1.9, 
95% CI 1.28 to 2.81, p = 0.0014), candidiasis (RR 3.95, 95% CI 1.65 to 9.47, p = 0.002), low Apgar score at 1 minute (RR 2.15, 95% 
CI 1.16 to 3.98, p = 0.015) and at 5 minutes (RR 1.95, 95% CI 1.03 to 3.69, p = 0.039), and perinatal mortality (RR 3.08, 95% CI 1.11 
to 8.52, p = 0.018).
Conclusions: Adherence to anti-diabetic therapy was sub-optimal and was associated with some adverse perinatal outcomes. 
Promotion of adherence, through routine individualised counselling, monitoring and assessment, is vital to minimise adverse 
outcomes.
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Introduction
Diabetes mellitus is a non-communicable disease which is a 
predominant cause of mortality in Africa.1 Its global prevalence 
has risen from 4.7% in 1980 to 8.5% in the adult population.1 The 
prevalence of diabetes in Zimbabwe is 5.7%.2 GDM is glucose 
intolerance diagnosed during pregnancy after the 24th week of 
gestation while type I and II diabetes in pregnancy are overt 
diabetes in previously diagnosed women. The prevalence of pre-
gestational type I and type II diabetes is included in the 
prevalence of diabetes mellitus.
The prevalence of GDM varies between 1% and 14% in all 
pregnancies depending on the genetic characteristics, 
environment of the population under study, screening and 
diagnostic methods employed and prevalence of type II diabetes 
mellitus.3 Diabetes in pregnancy increases the risk for various 
maternal and foetal complications such as pre-eclampsia, 
postpartum haemorrhage, infection, birth asphyxia, stillbirth 
and large for gestational age (LGA) infants.4 High rates of 
Caesarean delivery then result in macrosomia due to such 
reasons as cephalo-pelvic disproportion and foetal distress.4 The 
Hypoglycaemia and Adverse Pregnancy Outcomes (HAPO) 
cohort study demonstrated strong evidence of a continuous 
rather than threshold relationship of pregnancy outcomes with 
rising hyperglycaemia.5 Women with well-controlled blood 
glucose levels can give birth to healthy neonates.6
Adherence in pregnant women with diabetes is compromised by 
overload of advice from different healthcare professionals, self-
monitoring of blood glucose (SMBG) and strict dietary 
manipulation.7 Physiological demands of pregnancy such as 
nausea and vomiting compromise adherence to therapy. The 
main purpose of the study was to develop an adherence 
promotion framework for women with diabetes in pregnancy to 
improve adherence and perinatal outcomes. This article focuses 
on the association between non-adherence and perinatal 
outcomes.
Methods
This study was conducted at three central hospitals in Zimbabwe 
with a cohort of 157 pregnant women with diabetes in pregnancy. 
Consecutive sampling was used. Ethical approval was granted by 
the respective ethical review boards. All participants gave 
informed consent. Included in the study were pregnant women 
aged 18–45 years with diabetes in pregnancy. Excluded from the 
study were women who had not undergone adherence 
counselling, the very ill, the institutionalized and those who had 
previously participated in either the pilot or the main study. Data 
collection was done from September 2015 to January 2017 
through an interviewer-administered questionnaire. The 
questionnaire had sections on demographics, past and current 
health history, adherence to diet, physical activity and 
medications and perinatal outcomes. Adherence level of at least 
80%, measured by self-reports, was classified as good adherence 
while levels below 80% were poor. Participants were followed up 
from 20–24 weeks’ gestation up to 6 weeks post-delivery. Level of 
adherence was measured after recruitment and respondents 
were classified as either having good adherence or poor 
adherence. They were then followed up till 6 weeks after delivery 
for monitoring of perinatal outcomes. Data were analysed using 
the statistical package for Social Sciences (SPSS®) version 20 (IBM 
Corp, Armonk, NY, USA) and STATA (StataCorp LLC, College 
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Station, TX, USA). Descriptive statistics were used to analyse 
demographics, adherence levels and perinatal outcomes. 
Generalised linear regression modelling was used to analyse 
associations between adherence and perinatal outcomes and 
was reported as risk ratios.
Results
Demographic variables
Table 1 presents demographic variables. Forty (25.5%) 
participants had type I diabetes mellitus, 69 (43.9%) had type II 
while 48 (30.6%) had GDM. Fifty (31.8%) participants were aged 
between 30 and 34, 130 (82.8%) were married 113 (72.0%) had 
attained the ordinary level of education while 91 (58%) were 
unemployed.
Adherence to anti-diabetic therapy
Table 2 presents adherence to anti-diabetic therapy ranges. 
Twenty-six (16.6%) scored below 50%, 12 (7.6%) scored from 
50–59%, 19 (12.1%) scored from 60–69%, 42 (26.8%) scored from 
70–79%, 56 (35.6%) scored from 80–89% while 2 (1.3%) scored 
90% and above. Fifty-eight (36.9%) scored 80% and above.
Perinatal outcomes
Table 3 presents perinatal outcomes. Fifty-four (34.4%) had 
hypertensive disorders while 72 (45.9%) had Caesarean delivery. 
Fifty-three (33.8%) had macrosomia, 42 (26.8%) had low Apgar 
score at 1 minute and 39 (24.8%) had low Apgar score at 5 
minutes.
Table 4 presents associations between level of adherence and 
perinatal outcomes. There were significant associations with 
Caesarean delivery, vaginitis/candidiasis, low Apgar score at 1 
minute and at 5 minutes and perinatal mortality.
Discussion
The pregnancy state in diabetes requires even stricter adherence 
to therapy because of the detrimental effects of hyperglycaemia 
on both the mother and the foetus. In terms of type of diabetes, 
Table 1: Demographic variables (n = 157)
Variable Frequency Percentage Cumulative 
percentage
Type of diabetes:    
Type I 40 25.5 25.5
Type I1 69 43.9 69.4
GDM 48 30.6 100
Age in years:    
18–24 21 13.4 13.4
25–29 37 23.6 36.9
30–34 50 31.8 68.8
35–39 38 24.2 93
40–44 11 7 100
Marital status:    
Single 21 13.4 13.4
Married 130 82.8 96.2
Cohabiting 6 3.8 100
Level of education:    
None 1 0.6 0.6
Primary 18 11.5 12.1
Ordinary 113 72 84.1
Advanced 10 6.4 90.4
Tertiary 15 9.6 100
Employment status:    
Unemployed 91 58 58
Self employed 39 24.8 82.8
Employed 27 17.2 100
Table 2: Adherence to anti-diabetic therapy ranges (n = 157)
 Variable Frequency Percentage Cumulative 
percentage
< 50 26 16.6 16.6
50–59 (Poor) 12 7.6 24.2
60–69 (Poor) 19 12.1 36.3
70–79 (Poor) 42 26.8 63.1
80–89 (Good) 56 35.6 98.7
90–100 (Very good) 2 1.3 100.0
Table 3: Perinatal outcomes (n = 157)
Variable Frequency Percentage
PIH/pre-eclampsia/eclampsia 54 34.4
Caesarean delivery 72 45.9
Maternal DKA 8 5.1
Maternal hypoglycaemia 25 15.9
Candidiasis/vaginitis 31 19.7
Preterm birth 8 5.1
Perinatal mortality 25 15.9
Low Apgar score at one minute 42 26.8
Low Apgar score at five minutes 39 24.8
Macrosomia 53 33.8
Low birth weight 11 7
Neonatal hypoglycaemia 24 15.3
Table 4: Associations between level of adherence and perinatal 
outcomes (n = 157)
Variable Risk ratio Confidence interval p-value
Maternal outcomes:
Caesarean delivery 1.90  0.8 to 2.03 0.001*
Hypertension 1.28  0.8 to 2.03 0.305
Maternal DKA 1.76  0.38 to 4.59 0.473
Maternal hypogly-
caemia
1.50  0.68 to 3.34 0.312
Preterm birth 1.76  0.38 to 8.23 0.473
Vaginitis/candidiasis 3.95  1.65 to 9.47 0.002*
Neonatal outcomes:
Apgar < 7 at 1 minute 2.15  1.16 to 3.98 0.015*
Apgar < 7 at 5 minutes 1.95  1.03 to 3.69 0.039*
Macrosomia 0.89  0.57 to 1.4 0.619
Neonatal hypogly-
caemia
0.41  0.19 to 0.86 0.019*
Perinatal mortality 3.08 1.11 to 8.52 0.018*
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30.6% participants had GDM, 43.9% had pre-gestational type II 
diabetes while 25.5% had pre-gestational type I diabetes. This 
translates to 69.4% pre-gestational diabetes. Many studies 
conducted have reported much higher percentages of GDM in 
diabetes in pregnancy.8−11 The lower proportion of GDM in this 
study could be a reflection of inadequate screening for GDM in 
the setting due to lack of resources. In high-income countries 
GDM screening is an established part of antenatal care with 
specific procedures clearly defined in national guidelines while 
screening and management of GDM often is not part of routine 
care in the majority of low-resource settings.12 Guidelines are 
often absent in low-resource settings where, until now, GDM has 
received less attention than other causes of perinatal morbidity 
and mortality.12
The majority (82.8%) of participants were married. This presents 
an opportunity for male engagement in the care of women with 
diabetes in pregnancy. Spouses may provide social support to 
affirm healthy behaviours and social control to modify health 
behaviours in their partner’s diabetes management.13
This is even more relevant in this study where 58% were 
unemployed, meaning they could have depended on their 
husbands for support. In terms of education 88% had attained at 
least an ordinary level of education. Education is an important 
factor that has an influence on an individual’s attitude and 
outlook on various aspects of life.14 This presents an opportunity 
for effective health education of patients as they are able to 
internalise information given. The patient should know the basic 
principles regarding diet, maintenance of body weight, resting, 
and prevention of hypoglycaemia or deregulation of blood 
sugar. Optimum glucose control is vital in pregnancy and the 
intensity required necessitates a patient to learn, commit and 
execute.15 Findings of a study conducted in China revealed a 
positive correlation between knowledge of diabetes and self-
care behaviours. The score of self-care behaviours was positively 
related to diabetes knowledge (r = 0.176, p < 0.05) and attitude 
(r = 0.256, p < 0.01).16
Adherence to anti-diabetic therapy
Adherence to anti-diabetic therapy in this study referred to 
adherence to diet, medications and physical activity. Though 
measured separately, a composite score of overall adherence to 
therapy was calculated. Mean adherence to anti-diabetic therapy 
was 68.79%. This was low relative to the 80% adherence required 
for effective glycaemic control in diabetes. Fifty-eight (36.9%) 
participants scored above the recommended 80% or higher level 
of adherence. The majority of research on diabetes in pregnancy 
highlights its epidemiological, pathological and biological 
aspects with few authors researching the social and behavioural 
effects of the diagnosis from the viewpoint of the women 
affected.17 Adherence to therapy is one such social behavioural 
effect of diabetes in pregnancy. Such studies have been done in 
non-pregnant diabetic populations and similar rates of 
suboptimal adherence have been reported.18,19 Non-adherence 
in diabetes in pregnancy is a very significant problem because 
diabetes affects pregnant women more than the non-pregnant 
population due to the presence of more than the usual pregnancy 
discomforts. Glycaemic control in PGDM is complicated by the 
presence of physiological pregnancy changes while the need to 
learn about diabetes and management in a short space of time 
in GDM is a major challenge. Strict adherence to healthy lifestyle 
habits must be advocated in health policies worldwide to control 
diabetes mellitus, particularly in developing countries like 
Zimbabwe where access to health care and quality of health care 
are huge problems.
Perinatal outcomes
The most common maternal perinatal outcomes reported in the 
study were Caesarean delivery (45.9%) and PIH (34.4%). 
Caesarean delivery is common in diabetic pregnant mothers due 
to macrosomia.8 The incidence of macrosomia in this study was 
33.8%. The incidence of Caesarean delivery in this study is lower 
than incidences reported elsewhere in the literature. Rates of 
Caesarean delivery as high as 92.8%20 in India, and 89%21 in 
Nigeria have been reported in the literature. Some rates of 
Caesarean delivery reported were 74.3%,22 in Nigeria and 56% 
and 39.8% in GDM and in insulin-dependent groups respectively23 
in South Africa. González-Quintero et al. (2007) reported a 
Caesarean delivery rate of 48.5% in the USA.24 Studies have also 
demonstrated an increased risk of Caesarean delivery in diabetes 
in pregnancy.25 Vaginal delivery of such babies has been 
associated with shoulder dystocia, birth asphyxia and birth 
injury, thus the high rates of Caesarean delivery. Other studies 
have reported lower rates of Caesarean delivery than the one 
reported in this study. Ozumba et al. (2004) revealed an 
overall Caesarean section rate of 36% among diabetics in a study 
conducted in Nigeria.8 Previous Caesarean section and cephalo-
pelvic disproportion were the common indications for Caesarean 
delivery. Another study conducted in Taiwan reported a rate of 
Caesarean delivery of 31.6%.4 Hypertensive disorders in 
pregnancy are also indications for Caesarean delivery and in this 
study 34.4% participants had hypertensive disorders.
Hypertensive disorders of pregnancy are common in diabetes in 
pregnancy where they lead to higher maternal and foetal 
morbidity and also increase the risk for future cardiovascular 
events.26 The incidence of hypertensive disorders in this study 
was 34.4%. Poor adherence in this study that consequently 
influences glycaemic control, which is a risk factor for 
hypertension,27 could explain the high incidence of hypertensive 
disorders. This is lower than the incidence of hypertension 
complicating pregnancy of 40% to 45% in women with PGDM as 
reported by Cundy et al. (2002).28 Huddle (2005) reported an 
incidence of 13.1% of hypertension in an audit of outcome of 
diabetic pregnancy conducted in South Africa.23 Billionet et al. 
(2017) reported an increased risk of pre-eclampsia/eclampsia in 
PGDM mothers compared with GDM mothers in a study 
conducted in France.29
The rate of macrosomia in this study was 33.8%. Macrosomia is 
common in diabetes in pregnancy due to a rapid growth rate of 
the foetus as a result of high glucose levels crossing the placenta 
by facilitated diffusion during pregnancy.30 This rate is 
comparable to rates reported in other studies. González-
Quintero et al. (2007) reported rates of 15.7% and 19.8% for 
macrosomia and LGA respectively in the United States. Wang et 
al. (2013)31 reported a rate of macrosomia of 17%. Other studies 
have reported even higher rates of macrosomia. Murphy et al. 
(2011) reported a rate of macrosomia of 37.6% in type II diabetics 
and 52.9% in type I diabetics,32 while John et al. (2015) reported a 
rate of 49%.21 Opara et al. (2010) reported a rate of 61.7%. Billionet 
et al. (2017)29 and Wahabi et al. (2013)25 reported an increased risk 
of macrosomia in GDM. A high incidence of some complications 
of diabetes in pregnancy such as macrosomia may indicate 
poorer care for women with diabetes in pregnancy in low-
resource settings.33
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Other neonatal outcomes observed in the study were low Apgar 
score at 1 minute (26.8%), low Apgar score at 5 minutes (24.8%) 
and low birth weight (7%). Rates of low Apgar score could have 
been due to macrosomia and prematurity in the study. 
Hyperbilirubinemia may be seen in the first 24 to 72 hours of life. 
The presence of hyperglycaemia and hyperinsulinemia in 
diabetes in pregnancy result in impairment of placental blood 
flow and transplacental exchanges resulting in a state of chronic 
relative hypoxaemia.34 The rate of neonatal hyperbilirubinemia in 
this study was 7.6%. Gonzalez et al. (2007)23 reported a rate of 
10.1% in the USA while Opara et al. (2010)22 reported a rate of 
57.4% in Nigeria. Hyperbilirubinemia is common even in 
neonates born to non-diabetic mothers. In diabetes in pregnancy 
it is worsened by hyperglycaemia and hyperinsulinemia.
Association between adherence to anti-diabetic therapy and 
perinatal outcomes was a calculated composite score of total 
adherence to diet, physical activity and medications. It was 
measured using self-reports following an interviewer-
administered questionnaire. The study was conducted in a 
resource-limited setting where FPG, 1 hour and 2 hour 
postprandial glucose readings could not be done. Participants 
who had poor adherence (< 80%) were 1.9 times more likely to 
deliver by Caesarean section (risk ratio (RR) 1.9, 96% confidence 
interval (CI) 1.28–2.81, p = 0.0014) compared with women who 
had high adherence (≥ 80%). Findings of the HAPO study that 
looked at the association between maternal glycaemia and 
perinatal outcomes revealed a significant association between 
maternal glycaemia and Caesarean delivery.46 Adjusted odds 
ratios were calculated for adverse pregnancy outcomes associated 
with an increase in the fasting plasma glucose level of 1 SD (6.9 mg 
per decilitre [0.4 mmol per litre]), one-hour plasma glucose level 
of 1 SD (30.9 mg per decilitre [1.7 mmol per litre]), and two-hour 
plasma glucose level of 1 SD (23.5 mg per decilitre [1.3 mmol per 
litre]). The risk of Caesarean delivery was 1.11 (95% CI, 1.06–1.15), 
1.10 (1.06–1.15), and 1.08 (1.03–1.12). The risk of giving birth by 
Caesarean section increased by 11%, 10% and 8% with an increase 
in fasting, one-hour and two-hour postprandial blood glucose. 
This translates to increased risk with rising glycaemia For birth 
weight above the 90th percentile, the risk increased by 38%, 46% 
and 38% with an increase in fasting, one-hour and two-hour 
postprandial blood glucose respectively. For cord-blood serum 
C-peptide level above the 90th percentile, which is a measure of 
hyperinsulinemia, the risk increased by 55%, 46% and 37% with 
an increase in fasting, one-hour and two-hour postprandial blood 
glucose respectively. For neonatal hypoglycaemia, the risk 
increased by 8%, 13% and 10% with an increase in fasting, one-
hour and tw-hour postprandial blood glucose respectively.
Participants with poor adherence (< 80%) were 3.95 times more 
likely to have vaginal infections (RR 3.95, 95% CI 1.65–9.47, p = 
0.002) compared with women who had high adherence (≥ 80%). 
Diabetes and yeast infection can co-occur during pregnancy.47 
Uncontrolled blood sugar in diabetes in pregnancy is a major risk 
factor for candidiasis.47
The associations between adherence and other maternal 
perinatal outcomes were not significant. The relative risks for 
other maternal outcomes were hypertensive disorders (RR 1.28, 
95% CI 0.8–2.03, p < 0.305), maternal DKA (RR 1.76, 95% CI 0.38–
4.59, p < 0.473), maternal hypoglycaemia (RR 1.50, 95% CI 0.68–
3.34, p < 0.312) and preterm birth (RR 1.76, 95% CI 0.38–8.23, p < 
0.473). The Hypoglycaemia and Adverse Pregnancy Outcomes 
(HAPO) cohort study demonstrated strong evidence of a 
continuous rather than threshold relationship of pregnancy 
outcomes with rising hyperglycaemia.5
The rate of neonatal hypoglycaemia in this study was 15.3%. 
Hypoglycaemia is one of the most frequent complications of 
diabetes in the baby30,34 and the incidence ranges from 30% to 
50% depending on maternal glucose control during pregnancy, 
duration of labour, blood glucose level at the time of delivery 
and whether there was early or late feeding.30 This rate is higher 
than 9.3% reported by González-Quintero et al. (2007) in the 
USA.24 It is much lower than 63.8% reported by Opara et al. (2010) 
in Nigeria.22
The rate of perinatal mortality in the study was 15.9%. Perinatal 
mortality rate (PMR) is an important perinatal health indicator 
and is always higher in diabetic pregnancies than in the 
background PMR.35 It is driven by congenital malformations of 
the neonate.36 This rate could be comparable to the 124 per 1 000 
perinatal mortality rate reported earlier in the same setting.37 
Chirenje (1992) reported a PNM of 124 per 1 000 in infants born 
to diabetic mothers compared with 44 per 1 000 in those born to 
non-diabetic mothers.37 However, the higher rate observed in 
this current study could be attributed to the rising incidence of 
type II diabetes mellitus coupled with improved screening for 
GDM compared with almost three decades ago. High perinatal 
mortality rate might reflect poorer glycaemic control and poorer 
management of diabetes in pregnancy in the setting. Yang et al. 
(2006) reported a perinatal mortality rate of 11.5 per 1 000, 
compared with 4.8 per 1 000 that was estimated in 62 079 normal 
pregnancies in Nova Scotia.39 A French study on 289 pregnancies 
with type-1 diabetes mellitus reported an incidence of 66 per 
1 000,18,38−43 while a British study in 1 706 women with type 1 
diabetes mellitus reported an incidence of intrauterine deaths of 
25.8 per 1 000 and an incidence of perinatal mortality of 31.7 per 
1 000.36 High PNM rates could be indicative of poorer perinatal 
outcomes, probably due to poor glycaemic control and 
challenges in the management of diabetes in pregnancy in the 
setting. Lower rates have also been reported in the literature. 
Huddle (2005) reported a PNM of 4.5% in infants born to diabetic 
mothers.23 John et al. (2015) reported 11 perinatal deaths 
(perinatal mortality rate 90 per 1 000 deliveries) in women with 
diabetes in pregnancy.21 Other studies have reported an 
increased risk of perinatal mortality in PGDM compared with 
GDM.29,44 Comparison of PGDM and GDM in this setting might be 
difficult due to under-diagnosis of GDM resulting in small 
numbers compared with GDM, late booking of pregnancies and 
limited access to tests such as HBA1C to distinguish between 
true GDM and undiagnosed PGDM. In Saudi Arabia Wahabi et al. 
(2017)11 reported an increased risk of stillbirth (OR 3.66; 95% CI 
1.98–6.72) in neonates of mothers with pre-GDM while 
González-Quintero et al. (2007)24 reported a rate of still births in 
GDM of 0.3%.
The rate of prematurity in this study was 5.1%. This rate is lower 
than the rates reported by Murphy et al. (201) of 17.5% and 
37.1% in type II and type I diabetes respectively.32 The high rate 
reported by Murphy could reflect the preference for premature 
delivery in the presence of significant complications in order to 
save the mother’s and the baby’s health.45 Prematurity is a risk 
factor for other complications such as intrauterine growth 
restriction, low birth weight, respiratory distress syndrome, 
hypoglycaemia, hypocalcaemia, polycythaemia, intrauterine 
death, hyperbilirubinemia, several types of malformations, 
hypertrophic cardiomyopathy and asphyxia.45 Some studies 
have reported no differences in incidence of prematurity in 
women with GDM and those without25 while others have 
reported an increased risk of prematurity in diabetes in 
pregnancy.29
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Other neonatal outcomes observed in the study were low Apgar 
score at 1 minute (26.8%), low Apgar score at 5 minutes (24.8%) 
and low birth weight (7%). Rates of low Apgar score could have 
been due to macrosomia and prematurity in the study. 
Hyperbilirubinemia may be seen in the first 24 to 72 hours of life. 
The presence of hyperglycaemia and hyperinsulinemia in 
diabetes in pregnancy result in impairment of placental blood 
flow and transplacental exchanges resulting in a state of chronic 
relative hypoxaemia.34 The rate of neonatal hyperbilirubinemia in 
this study was 7.6%. Gonzalez et al. (2007)23 reported a rate of 
10.1% in the USA while Opara et al. (2010)22 reported a rate of 
57.4% in Nigeria. Hyperbilirubinemia is common even in 
neonates born to non-diabetic mothers. In diabetes in pregnancy 
it is worsened by hyperglycaemia and hyperinsulinemia.
Association between adherence to anti-diabetic therapy and 
perinatal outcomes was a calculated composite score of total 
adherence to diet, physical activity and medications. It was 
measured using self-reports following an interviewer-
administered questionnaire. The study was conducted in a 
resource-limited setting where FPG, 1 hour and 2 hour 
postprandial glucose readings could not be done. Participants 
who had poor adherence (< 80%) were 1.9 times more likely to 
deliver by Caesarean section (risk ratio (RR) 1.9, 96% confidence 
interval (CI) 1.28–2.81, p = 0.0014) compared with women who 
had high adherence (≥ 80%). Findings of the HAPO study that 
looked at the association between maternal glycaemia and 
perinatal outcomes revealed a significant association between 
maternal glycaemia and Caesarean delivery.46 Adjusted odds 
ratios were calculated for adverse pregnancy outcomes associated 
with an increase in the fasting plasma glucose level of 1 SD (6.9 mg 
per decilitre [0.4 mmol per litre]), one-hour plasma glucose level 
of 1 SD (30.9 mg per decilitre [1.7 mmol per litre]), and two-hour 
plasma glucose level of 1 SD (23.5 mg per decilitre [1.3 mmol per 
litre]). The risk of Caesarean delivery was 1.11 (95% CI, 1.06–1.15), 
1.10 (1.06–1.15), and 1.08 (1.03–1.12). The risk of giving birth by 
Caesarean section increased by 11%, 10% and 8% with an increase 
in fasting, one-hour and two-hour postprandial blood glucose. 
This translates to increased risk with rising glycaemia For birth 
weight above the 90th percentile, the risk increased by 38%, 46% 
and 38% with an increase in fasting, one-hour and two-hour 
postprandial blood glucose respectively. For cord-blood serum 
C-peptide level above the 90th percentile, which is a measure of 
hyperinsulinemia, the risk increased by 55%, 46% and 37% with 
an increase in fasting, one-hour and two-hour postprandial blood 
glucose respectively. For neonatal hypoglycaemia, the risk 
increased by 8%, 13% and 10% with an increase in fasting, one-
hour and tw-hour postprandial blood glucose respectively.
Participants with poor adherence (< 80%) were 3.95 times more 
likely to have vaginal infections (RR 3.95, 95% CI 1.65–9.47, p = 
0.002) compared with women who had high adherence (≥ 80%). 
Diabetes and yeast infection can co-occur during pregnancy.47 
Uncontrolled blood sugar in diabetes in pregnancy is a major risk 
factor for candidiasis.47
The associations between adherence and other maternal 
perinatal outcomes were not significant. The relative risks for 
other maternal outcomes were hypertensive disorders (RR 1.28, 
95% CI 0.8–2.03, p < 0.305), maternal DKA (RR 1.76, 95% CI 0.38–
4.59, p < 0.473), maternal hypoglycaemia (RR 1.50, 95% CI 0.68–
3.34, p < 0.312) and preterm birth (RR 1.76, 95% CI 0.38–8.23, p < 
0.473). The Hypoglycaemia and Adverse Pregnancy Outcomes 
(HAPO) cohort study demonstrated strong evidence of a 
continuous rather than threshold relationship of pregnancy 
outcomes with rising hyperglycaemia.5
The rate of neonatal hypoglycaemia in this study was 15.3%. 
Hypoglycaemia is one of the most frequent complications of 
diabetes in the baby30,34 and the incidence ranges from 30% to 
50% depending on maternal glucose control during pregnancy, 
duration of labour, blood glucose level at the time of delivery 
and whether there was early or late feeding.30 This rate is higher 
than 9.3% reported by González-Quintero et al. (2007) in the 
USA.24 It is much lower than 63.8% reported by Opara et al. (2010) 
in Nigeria.22
The rate of perinatal mortality in the study was 15.9%. Perinatal 
mortality rate (PMR) is an important perinatal health indicator 
and is always higher in diabetic pregnancies than in the 
background PMR.35 It is driven by congenital malformations of 
the neonate.36 This rate could be comparable to the 124 per 1 000 
perinatal mortality rate reported earlier in the same setting.37 
Chirenje (1992) reported a PNM of 124 per 1 000 in infants born 
to diabetic mothers compared with 44 per 1 000 in those born to 
non-diabetic mothers.37 However, the higher rate observed in 
this current study could be attributed to the rising incidence of 
type II diabetes mellitus coupled with improved screening for 
GDM compared with almost three decades ago. High perinatal 
mortality rate might reflect poorer glycaemic control and poorer 
management of diabetes in pregnancy in the setting. Yang et al. 
(2006) reported a perinatal mortality rate of 11.5 per 1 000, 
compared with 4.8 per 1 000 that was estimated in 62 079 normal 
pregnancies in Nova Scotia.39 A French study on 289 pregnancies 
with type-1 diabetes mellitus reported an incidence of 66 per 
1 000,18,38−43 while a British study in 1 706 women with type 1 
diabetes mellitus reported an incidence of intrauterine deaths of 
25.8 per 1 000 and an incidence of perinatal mortality of 31.7 per 
1 000.36 High PNM rates could be indicative of poorer perinatal 
outcomes, probably due to poor glycaemic control and 
challenges in the management of diabetes in pregnancy in the 
setting. Lower rates have also been reported in the literature. 
Huddle (2005) reported a PNM of 4.5% in infants born to diabetic 
mothers.23 John et al. (2015) reported 11 perinatal deaths 
(perinatal mortality rate 90 per 1 000 deliveries) in women with 
diabetes in pregnancy.21 Other studies have reported an 
increased risk of perinatal mortality in PGDM compared with 
GDM.29,44 Comparison of PGDM and GDM in this setting might be 
difficult due to under-diagnosis of GDM resulting in small 
numbers compared with GDM, late booking of pregnancies and 
limited access to tests such as HBA1C to distinguish between 
true GDM and undiagnosed PGDM. In Saudi Arabia Wahabi et al. 
(2017)11 reported an increased risk of stillbirth (OR 3.66; 95% CI 
1.98–6.72) in neonates of mothers with pre-GDM while 
González-Quintero et al. (2007)24 reported a rate of still births in 
GDM of 0.3%.
The rate of prematurity in this study was 5.1%. This rate is lower 
than the rates reported by Murphy et al. (201) of 17.5% and 
37.1% in type II and type I diabetes respectively.32 The high rate 
reported by Murphy could reflect the preference for premature 
delivery in the presence of significant complications in order to 
save the mother’s and the baby’s health.45 Prematurity is a risk 
factor for other complications such as intrauterine growth 
restriction, low birth weight, respiratory distress syndrome, 
hypoglycaemia, hypocalcaemia, polycythaemia, intrauterine 
death, hyperbilirubinemia, several types of malformations, 
hypertrophic cardiomyopathy and asphyxia.45 Some studies 
have reported no differences in incidence of prematurity in 
women with GDM and those without25 while others have 
reported an increased risk of prematurity in diabetes in 
pregnancy.29
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